SIGN UP
LOG IN
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga·08/08/2025 21:08:06
Listen to the news
Gainers
- Gain Therapeutics (NASDAQ:GANX) stock increased by 9.4% to $1.62 during Friday's after-market session. The market value of their outstanding shares is at $51.5 million.
- Clover Health Investments (NASDAQ:CLOV) stock increased by 7.8% to $2.35. The company's market cap stands at $1.1 billion. As per the press release, Q2 earnings came out 3 days ago.
- XTL Biopharmaceuticals (NASDAQ:XTLB) shares increased by 7.51% to $1.43. The market value of their outstanding shares is at $12.5 million.
- Calidi Biotherapeutics (AMEX:CLDI) stock rose 7.18% to $5.37. The company's market cap stands at $16.5 million. As per the press release, Q2 earnings came out today.
- Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 5.55% to $15.0. The company's market cap stands at $133.5 million. The company's, Q2 earnings came out 2 days ago.
- SenesTech (NASDAQ:SNES) stock increased by 5.33% to $4.94. The market value of their outstanding shares is at $18.8 million. The company's, Q2 earnings came out yesterday.
Losers
- EUDA Health Holdings (NASDAQ:EUDA) shares declined by 13.0% to $2.35 during Friday's after-market session. The market value of their outstanding shares is at $105.1 million.
- Ontrak (NASDAQ:OTRK) stock fell 8.67% to $0.34. The company's market cap stands at $2.4 million.
- SINTX Technologies (NASDAQ:SINT) shares decreased by 7.59% to $2.68. The market value of their outstanding shares is at $6.7 million.
- iSpecimen (NASDAQ:ISPC) shares decreased by 6.26% to $1.2. The market value of their outstanding shares is at $7.1 million.
- Assembly Biosciences (NASDAQ:ASMB) shares fell 6.14% to $22.5. The company's market cap stands at $162.0 million. As per the news, the Q2 earnings report came out 2 days ago.
- Orchestra BioMed Hldgs (NASDAQ:OBIO) shares declined by 5.91% to $2.55. The company's market cap stands at $140.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.